US Patent Litigations are now available. Check here

Explore Blueprint Medicines's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 17, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3773589Nov 1, 2023Ret Inhibitor For Use In Treating Cancer Having A Ret Alteration1
EP3856341Sep 6, 2023Crystalline Forms Of (S)-1-(4-Fluorophenyl)-1-(2-(4-(6-(1-Methyl-1H-Pyrazol-4-Yl)Pyrrolo[2,1-F][1,2,4]Triazin-4-Yl)Piperazinyl)-Pyrimidin-5-Yl)Ethan-1-Amine And Methods Of Making1